Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.

作者: Nicholas Mitsiades , Vassiliki Poulaki , Vassiliki Kotoula , Alvaro Leone , Maria Tsokos

DOI: 10.1016/S0002-9440(10)65708-2

关键词:

摘要: Fas ligand (FasL) exists in transmembrane and soluble forms induces apoptosis on cross-linking with the receptor. We evaluated biological significance of FasL 61 tumor tissues 9 cell lines Ewing's sarcoma family tumors (ESFT). was present 62.5% 79.4% primary ESFT. Metastatic had higher expression (95%), suggesting association a metastatic phenotype. detected cytoplasm membrane ESFT cells by immunofluorescence. Western blotting revealed cytosolic extracts conditioned media. Both induced Fas-sensitive Jurkat co-culture experiments or their Treatment phenanthroline synthetic metalloproteinase inhibitor BB-3103 reduced levels media, that ESFT, is processed released extracellular milieu. The may serve to attack immune system and/or interfere binding Fas, results down-regulation FasL. Synthetic inhibitors modify ratio

参考文章(54)
Andreas Villunger, Alexander Egle, Ingrid Marschitz, Marion Kos, Günther Böck, Heinz Ludwig, Stephan Geley, Reinhard Kofler, Richard Greil, Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood. ,vol. 90, pp. 12- 20 ,(1997) , 10.1182/BLOOD.V90.1.12
L.J. Denis, J. Verweij, Matrix metalloproteinase inhibitors: Present achievements and future prospects Investigational New Drugs. ,vol. 15, pp. 175- 185 ,(1997) , 10.1023/A:1005855905442
M. Tanaka, T. Suda, T. Takahashi, S. Nagata, Expression of the functional soluble form of human fas ligand in activated lymphocytes. The EMBO Journal. ,vol. 14, pp. 1129- 1135 ,(1995) , 10.1002/J.1460-2075.1995.TB07096.X
Stetler-Stevenson Wg, Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix American Journal of Pathology. ,vol. 148, pp. 1345- 1350 ,(1996)
A Oehm, I Behrmann, W Falk, M Pawlita, G Maier, C Klas, M Li-Weber, S Richards, J Dhein, B.C. Trauth, Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. Journal of Biological Chemistry. ,vol. 267, pp. 10709- 10715 ,(1992) , 10.1016/S0021-9258(19)50076-X
G C Starling, S J Klebanoff, W C Liles, P M Davis, P A Kiener, B M Rankin, J A Ledbetter, Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. Journal of Immunology. ,vol. 159, pp. 1594- 1598 ,(1997)
David G. Poplack, Philip A. Pizzo, Principles and Practice of Pediatric Oncology ,(1989)
E N Spremulli, D L Dexter, Human tumor cell heterogeneity and metastasis. Journal of Clinical Oncology. ,vol. 1, pp. 496- 509 ,(1983) , 10.1200/JCO.1983.1.8.496
Pascal Schneider, Nils Holler, Jean-Luc Bodmer, Michael Hahne, Karl Frei, Adriano Fontana, Jürg Tschopp, Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity Journal of Experimental Medicine. ,vol. 187, pp. 1205- 1213 ,(1998) , 10.1084/JEM.187.8.1205
T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green, T. A. Ferguson, Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege Science. ,vol. 270, pp. 1189- 1192 ,(1995) , 10.1126/SCIENCE.270.5239.1189